Updates from Leading Experts
STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management
Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study of implementation of GDMT heart failure therapy that assessed the safety, tolerability of optimization of guideline directed...
28 March 2023
Prof Alexandre Mebazaa
CANVAS (CANagliflozin cardioVascular Assessment Study): NT-proBNP and CVD risk reduction
Can you give us a short description of the CANVAS program? The CANVAS (CANagliflozin cardioVascular Assessment Study) program was a set of two trials, whose goal was to evaluate the...
1 July 2021
Dr James L Januzzi
Related Links
- MASH and Hepatic Fibrosis: Intersecting Metabolic Pathways
- How to Manage PMI? - Practical Implementation in Ramathibodi Hospital
- Lp(a) Screening at Least Once a Lifetime! Unwrapping the What, Why and How's of Lipoprotein(a)
- NT-proBNP as a predictor of Cardio-renal Complications in PwD
- Safety of Rx Optimisation Post AHF Hospitalization
- Practical Implementation of GDMT Optimisation - The ATP in NZ
- Use of Rapid Algo for Suspected AMI - Faster Triage of ED Patients
- Navigating Cardiotoxicity - Value of Cardiac Biomarkers
- DROP Asian ACS - Study Results and Practical Approach
- The Importance of Early Diagnosis and Management of AHF
- Integrative Approaches to Managing Diabetes and Cardiovascular Disease
- Optimising GDMT Post AHF Discharge - APAC APSC Consensus Highlights
- Initiation of GDMT Therapy in Patients Discharged Post AHF - What are the Guardrails?
- Enhancing Diabetes and Cardiovascular Management with Continuous Glucose Monitoring
- New Frontiers for Risk Stratification Assays for Acute Coronary Syndrome - The Gen6 Assay for hs cTnT
- NT-proBNP for Rapid Optimisation of GDMT in AHF Patients in Japan
- ACC 2025 Spotlight: DROP-Asian ACS Interim Analysis Highlights Regional Gains in NSTEMI Care
- Empowering the Everyday: AI-enabled CGM Is the Next Leap in Diabetes Care
- Lipoprotein(a) in clinical practice
- Diabetes and Hajj: Doctor's Awareness Program
- STRONG-HF Japan Study
- Diabetes and Ramadan: Public Awareness Program
- Innovative Strategies to Optimise Heart Failure GDMT at Prince Wales Hospital’s Heart Failure Clinic
- STRONG-HF Recommended in Updated China National Heart Failure Guideline 2023
- Rapid Titration (RaT) Pathway For Optimising Heart Failure GDMT with comprising several hospitals in Northland
- Ramadan & Diabetes
- International Speaker Program (ISP) From Diabetes to Wellbeing: A Global Dialogue on Holistic Health
- Reducing Mortality and Readmission with HF Multidisciplinary Model of Care
- Implementing 0/1-Hour Algorithm using High-Sensitivity Cardiac Troponin in the Emergency Department
- Culturally Sensitive Diabetes Care
- What Causes Falsely High & Low HbA1c Reading?
- Menopause and Diabetes
- World Anaesthesia Day: Dawn of a New Era in the Management of Perioperative Myocardial Infarction (PMI)
- EMPORIUM - Full Throttle Against HF: From Detection to Protection
- Every Heartbeat Counts: Take Action & Make an Impact This World Heart Day
- The effectiveness of telemonitoring and integrated personalised diabetes management in people with insulin-treated type 2 diabetes mellitus
- Screening for Occult Heart Failure (HF) in Type 2 Diabetes Mellitus (T2DM) using NT-proBNP
- Value of biomarker in HFpEF Diagnosis
- Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)
- Communicating the value of CVD screening in T2DM to patients
- Lipoprotein(a): The science behind the Risk Factor
- Sex-specific Differences in Heart Failure
- Management of CVD in Patients with Diabetes
- STRONG-HF: Enhancing GDMT regimen in Asia
- Heart Failure Care Beyond City Limits: Insights from a Cardiologist
- Implementation of STRONG-HF protocol in heart failure management: an Australian perspective
- Unleashing the Power of STRONG-HF: Enabling Transformation in Heart Failure Management Across China
- When every minute counts: A deep dive into IJN Malaysia's quest for rapid triage for chest pain patients in the ED
- Reshaping HF Management at NHCS
- Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients
- Elevating CVD management in APAC to its Zenith- with Cardiac biomarkers
- Quantum leap in reducing rehospitalization in HF by 70-80% - How and where?
- 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
- STRONG-HF: Rapid Uptitration of Guideline Directed Medical Therapy for Heart Failure
- Guidelines Interpretation - Guidelines for the management of chronic heart failure in dialysis patients in China
- Heart failure management in Australia and the role of NT-proBNP in monitoring and treatment
- Download APAC STRONG-HF Master Pack: First-hand Insights from Prof Mebazaa on Heart Failure Treatment Monitoring
- Perioperative myocardial injury (PMI) management: Challenges and feasibility of active screening in non-cardiac surgeries
- Heart Failure Management in India - Overcoming Present Challenges
- STRONG-HF Trial highlighting benefits of treatment optimisation
- STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management
- NT-proBNP and ECHO in heart failure - do they always go hand in hand?
- Rapid ACS Rule Out in Emergency Patients
- How to Implement the 0-h/1-h Algorithm to your Institute?
- High Sensitivity Cardiac Troponins and ACS - the Malaysian Experience
- APAC Heart Failure Gap Report
- Rational use of troponin and optimal management of cardiovascular diseases
- Value of NT-ProBNP for Treatment Monitoring in CHF
- The evidence for 0/1-hour algorithm for Asia? DROP-Asian ACS Study
- Process Optimization for Emergency hs-TnT Detection
- Clinical Application NT-proBNP in CKD (Chronic Kidney Diseases) Patients with Cardiovascular Diseases
- Uncovering the Cardio-renal Risks of Chinese T2DM patients: Back to the Future with CUHK!
- High Sensitivity Troponin vs Conventional Troponin: An Expert View
- The rationale for the use of hs-cTn in the optimal management of ACS
- Management of Diabetes in Japan - Can Patients Play a More Significant Role?
- T2DM Patient Support Program in Hong Kong and the Value of NT-proBNP
- Role of Diagnostics: NT-proBNP in management of Heart Failure
- Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients
- Rapid algorithms for hs-cTn in ED: Boon or Bane?
- 2021 ESC Heart Failure Guidelines: What's new?
- Heart Failure in Hong Kong- Present Challenges and Future Strategies
- Tips for implementing ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients
- Rapid Algorithms for Faster Triage of ED Patients with Suspected AMI - What Are We Waiting For?
- Comparing the ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients
- STROKESTOP II Study: Precision risk screening for atrial fibrillation in elderly
- Atrial Fibrillation in Elderly: Screening tools and role of NT-proBNP
- Advantages of early NT-proBNP testing in patients suspected with heart failure
- NT-proBNP: Increasing Clinical Confidence in Heart Failure Management
- What is the Peptide for Life initiative?
- Digital Prediction Platforms: A catalyst towards personalized CVD prognosis
- Heart Failure in Asia - Present Challenges and Future Strategies
- Perioperative Myocardial Infarction in Non-Cardiac Surgery – Why Measuring Troponin is Important?
- Heart Failure Prevention in T2DM - Essence of JCS/JDS joint consensus
- Clinical Cases: Differentiating acute from chronic cardiac conditions
- Clinical Cases: Diagnostic relevance of elevated hs-cTnT
- Clinical Cases from Korea: Serial NT-proBNP measurement and Heart Failure prognosis
- Clinical Cases from Korea: NT-proBNP for Differential diagnosis of patients with dyspnoea
- Clinical Cases from Korea: Value of NT-proBNP in Cardiomyopathy
- Clinical Cases from Korea: High NT-proBNP levels useful in differential diagnosis of HF
- CVD Management in T2DM - JCS and JDS Joint Consensus
- ESC Recommendation: High sensitivity troponin assay vs conventional assay
- ESC Recommendation: Rapid algorithms using hs troponin in ED
- Dr David Sim's Clinical Cases: NT-proBNP in Heart Failure Patients
- CANVAS (CANagliflozin cardioVascular Assessment Study): NT-proBNP and CVD risk reduction
- Clinical Cases: Elevations of hs-TnT in Non-cardiac Conditions
- Clinical Cases: hs-TnT in Patients with End Stage Renal Failure
- Clinical Cases: Serial Monitoring Differentiates Acute and Chronic hs-TnT Elevation
- Dr Lee's Clinical Cases: hs-TnT Chronic Elevation non-AMI cases
- Dr Lee's Clinical Cases: hs-TnT Early "Rule-In" for AMI
- FAQ: NT-proBNP Interpretation in Multiple Scenarios
- FAQ: NT-proBNP vs Cardiac Medications
- FAQ: Role of NT-proBNP in Heart Failure Management
- At the forefront of Acute Coronary Syndrome management in ED
- What should we take note of when using hs-TnT for CKD patient?
- Clinical Relevance - High-Sensitivity Troponin Results Influenced by Age
- Clinical Relevance of hs-TnT gender specific cut-offs
- Recommended Steps to Implement 0h/1h Algorithm in Asia
- Setting sight on breakthrough diagnostics
- Benefits of 0h/1h Algorithm in a Thai Institution
- Benefits of 0h/1h Algorithm to Patients in Asia
- Recommendations of IFCC on Natriuretic Peptide Testing
- How will NT-proBNP testing evolve in the future?
- Is NT-proBNP validated for different population groups?
- Reference ranges for NT-proBNP & hs-TnT in Asian populations
- How to Implement ESC Rapid Algorithm Successfully?
- The Changes in Rapid Algorithms for Acute Coronary Syndrome
- Sex Differences in Troponin Levels - affecting high-sensitivity cardiac troponin (hs-cTn) levels
- DAPA-HF and EMPEROR-Reduced Study Highlights
- The role of biomarkers in HF
- Digital health in HF management
- Benefits of the 0h/1h algorithm in a Japanese institution
- Serial testing of hs cTn rules out low risk of AMI
- Patient Case Studies Using 0h/1h Algorithm
- Latest IFCC Recommendations for Natriuretic Peptides in Heart Failure - Analytics and Clinical Considerations
- BNP vs NT-proBNP: An Expert View
- Natriuretic Peptide Measurement during ARNi Treatment
- Impact of ARNi Therapy on Natriuretic Peptide Use
- Summary of APSC High Sensitivity Troponin T Consensus
- NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice
- How to Use NT-proBNP for Prognosis and Monitoring?
- What Should Hospitals Consider when Implementing Rapid Algorithm?
- Early triage of patients with acute chest pain with hs-TnT 0h/1h Algorithm
- APSC hs-TnT Consensus & Future Use of Biomarker in T2DM & COVID-19
- TRAPID-AMI sub-study: Use of very low concentration of hs-TnT to rule out AMI using a single blood test
- Benefits of hs-Tn 0h/1h Algorithm in ED & Hospital
- TRAPID-AMI Study: hs-TnT for Rapid Rule In/ Out of AMI
- Benefits of hs-Tn 0h/1h Algorithm to Chest Pain Patients
- Management of Cardiovascular Risks of COVID-19 Patients
- How NT-proBNP Made a Difference: Dr Januzzi's Patient Story
- Impact of High-Sensitivity Cardiac Troponin (hs-Tn) on Further Cardiac Testing in Suspected AMI Patients
- Management of COVID-19 and the Heart, Experience from Front Line
- Advantages of Switching from Conventional to High-Sensitivity Troponin
- How hs-TnT Made a Difference - Dr Twerenbold's Story
- How NT-proBNP Made a Difference: Dr Richards' Patient Story
- Natriuretic Peptides in the Latest ESC & AHA HF Guidelines
- Role of Natriuretic Peptides in Patients with Dypsnea
- Novel Biomarker-based Risk Score in AF: ABC Risk Score
- Understanding Reasons for Increased Troponin Levels
- hs-TnT Rapid Diagnosis of AMI- ESC 0h/3h Algorithm
- hs-TnT Rapid Diagnosis of AMI- ESC 0h/1h Algorithm
2800+ Healthcare Professionals have cardiac insights delivered to their inbox
Sign up to receive the latest updates via your email
Keep me informed